SCHEMBL2473934

SCHEMBL2473934

COC(=O)c1ccc(Cl)cc1SC(=O)N(C)C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.53
NR4A2 P43354 2/20 0.43
RXFP1 Q9HBX9 1/20 0.43
HPGD P15428 3/20 0.43
MAPT P10636 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
HTT P42858 2/20 0.43
NPC1 O15118 1/20 0.43
NFKB1 P19838 1/20 0.43
RAB9A P51151 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ALDH1A1 P00352 6/20 0.41
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
CYP1A2 P05177 2/20 0.39
CYP2C19 P33261 2/20 0.39
CYP3A4 P08684 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13159056 0.88 ABL1 (0.49) ABL1NR4A2RXFP1HPGDMAPT
SCHEMBL10610561 0.84 NR4A2 (0.42) ABL1NR4A2HPGDMAPTSMN1; SMN2
SCHEMBL2472875 0.83 SMN1; SMN2 (0.49) HPGDMAPTSMN1; SMN2HTTRAB9A
SCHEMBL2472153 0.82 HPGD (0.39) ABL1HPGDMAPTSMN1; SMN2HTT
SCHEMBL2468670 0.82 NR4A2 (0.43) NR4A2HPGDMAPTSMN1; SMN2HTT
SCHEMBL4289129 0.82 CA12 (0.38) ABL1HPGDMAPTSMN1; SMN2L3MBTL1
SCHEMBL2962760 0.82 NPC1 (0.43) HPGDMAPTSMN1; SMN2HTTNPC1
SCHEMBL4071201 0.80 ABL1 (0.60) ABL1NR4A2RXFP1HPGDMAPT
SCHEMBL9660294 0.79 ABL1 (0.53) ABL1NR4A2RXFP1MAPTSMN1; SMN2
SCHEMBL9814816 0.79 TDP1 (0.45) MAPTSMN1; SMN2HTTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022015624-A1 SUBSTITUTED DIHYDROPYRAZINEDIONES AS MODULATORS OF THE NMDA RECEPTOR SCHRÖDINGER, INC. (US) 2022-01-20 WO disclosed
EP-2370422-B1 THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS FIBROGEN INC (US) 2019-06-05 EP disclosed
US-9149476-B2 Thiochromene derivatives as HIF hydroxylase inhibitors FIBROGEN, INC. (US) 2015-10-06 US disclosed
US-20150182528-A1 THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS FIBROGEN, INC. 2015-07-02 US disclosed
US-8927591-B2 Thiochromene derivatives as HIF hydroxylase inhibitors FIBROGEN, INC. (US) 2015-01-06 US disclosed
US-20110305776-A1 THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS FIBROGEN, INC. (US) 2011-12-15 US disclosed
EP-2370422-A1 THIOCHROMENE DERIVATIVES AS HIP HYDROXYLASE INHIBITORS Fibrogen, Inc. (US) 2011-10-05 EP disclosed
WO-2010056767-A1 THIOCHROMENE DERIVATIVES AS HIP HYDROXYLASE INHIBITORS FIBROGEN, INC. (US) 2010-05-20 WO disclosed
EP-0262845-A1 Heterocyclic substituted azole derivatives FISONS plc (GB) 1988-04-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110305776-A1 THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS HIF1AN, HIF1A, EGLN2 ABL1 558/4885NR4A2 622/4885RXFP1 2770/4885
US-20150182528-A1 THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS HIF1AN, HIF1A, EGLN2 ABL1 558/4885NR4A2 622/4885RXFP1 2770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.